The Canadian Rheumatology Association strongly recommends that access to citrate-free Humira be made available for Canadian children requiring treatment with Humira.
In Canada, a new jurisdiction inaugurates mandatory switching to biosimilars.
The Northwest Territories has become the fifth Canadian jurisdiction to mandate switching to biosimilars for patients in the public health system. The Northwest Territories is a sparsely populated (41,000) wilderness area that is known for its native settlements, European immigration, fur trade and gold prospecting history (Yellowknife).
Public officials said in a statement that the biosimilar switching policy will be consistent with those already established in British Columbia, New Brunswick, Alberta, and Quebec. Canada has begun imposing mandatory biosimilar switching programs following lackluster voluntary biosimilar uptake. Biosimilars are highly similar to the original brand drugs they reference and just as safe and efficacious. They enter the market at discounts to the originator drugs and help to bring down the costs of health care and improve patient access to critical medicines.
The Canadian Rheumatology Association strongly recommends that access to citrate-free Humira be made available for Canadian children requiring treatment with Humira.
A statement by Biosimilars Canada, a trade association of biosimilars producers, explained that in the Northwest Territories switching will become mandatory for patients on 10 biologic reference drugs for which biosimilars are available, within the following therapeutic areas: arthritis, diabetes, inflammatory bowel disease, and psoriasis. The transition to biosimilars must occur by June 20, 2022.
“The full benefits of biosimilars cannot be realized unless drug plans adopt policies that support their expanded use with the implementation of successful biosimilar transitioning or “switching” policy,” the group said.
Biosimilar Substitution Can Reduce TCOC, Improve Provider Performance in Value-Based Payment Models
December 7th 2023A simulation study estimated the impact of biosimilar substitution on total cost of care (TCOC) and provider financial performance in the final performance period of the Oncology Care Model.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity
November 29th 2023A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.